Acquired Company

Bioblast Pharma Ltd acquired Enlivex Therapeutics Ltd and after closing the merger the surviving company was renamed Enlivex Therapeutics Ltd with the trading symbol ENLV.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel. Show more

14 Einstein Street, Ness Ziona, 7403618, Israel

https://www.enlivex.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

246.9M

52 Wk Range

$0.66 - $2.10

Previous Close

$1.04

Open

$1.03

Volume

855,357

Day Range

$1.03 - $1.23

Enterprise Value

6.238M

Cash

18.2M

Avg Qtr Burn

-1.968M

Insider Ownership

0.46%

Institutional Own.

0.82%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Allocetra (Immunotherapy) Details Treatment of organ failure associated with Sepsis	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Allocetra (Immunotherapy) Details Knee osteoarthritis	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Allocetra (Immunotherapy) Details Basal thumb osteoarthritis	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Allocetra (Immunotherapy) Details TMJ Osteoarthritis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Allocetra (Immunotherapy) + Chemotherapy Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Allocetra (Immunotherapy) +/_ anti-PD1 checkpoint inhibitors Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tovinontrine (IMR-687) Details Beta thalessemia, Genetic disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Allocetra (Immunotherapy) Details COVID-19, Non-alcoholic steatohepatitis , Liver disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Allocetra (Immunotherapy) Details Bone marrow transplantation, Prevention of post-bone marrow transplantations complications	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tovinontrine (IMR-687) Details Sickle cell disease, Genetic disorder, Blood disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.